Panobinostat (LBH589) Plus Everolimus (RAD001) in Patients With Relapsed and Refractory Lymphoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

March 31, 2014

Study Completion Date

March 31, 2014

Conditions
Lymphoma
Interventions
DRUG

Panobinostat

Starting dose of 10 mg by mouth per day, self-administered (by patients), three times per week

DRUG

Everolimus

Starting dose of 5 mg every day by mouth with 1 cup (8 ounces) of water, in morning after eating a low-fat meal.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER